This article is more than 5 years old. Information may no longer be current.

Study initiated to compare SLT, medication for glaucoma

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

PHILADELPHIA — A clinical trial comparing the efficacy of selective laser trabeculoplasty to conventional medical management as a monotherapy for open-angle glaucoma is now under way at 17 sites nationwide. The study is being coordinated here at Wills Eye Hospital and in New Orleans at Tulane University.

Called the SLT/MED, the multicenter, prospective, randomized, controlled study will investigate the efficacy of selective laser trabeculoplasty (SLT) as an initial treatment for open-angle glaucoma, compared to medical management.

About 20 patients will be recruited per site, with a goal of enrolling 340 patients total. Jay Katz, MD, of Wills Eye Hospital, said SLT will be performed using the Lumenis Selecta Glaucoma Laser System.

“The trial will discern whether SLT is equal to or better than the use of medication to lower eye pressure. Use of the SLT laser could produce fewer drug-related side effects, minimize the cost and lead to a better quality of life,” Dr. Katz said.